Chong‐Rui Xu

7.3k total citations · 3 hit papers
122 papers, 4.4k citations indexed

About

Chong‐Rui Xu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Chong‐Rui Xu has authored 122 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Pulmonary and Respiratory Medicine, 73 papers in Oncology and 25 papers in Cancer Research. Recurrent topics in Chong‐Rui Xu's work include Lung Cancer Treatments and Mutations (83 papers), Lung Cancer Research Studies (33 papers) and Colorectal Cancer Treatments and Studies (29 papers). Chong‐Rui Xu is often cited by papers focused on Lung Cancer Treatments and Mutations (83 papers), Lung Cancer Research Studies (33 papers) and Colorectal Cancer Treatments and Studies (29 papers). Chong‐Rui Xu collaborates with scholars based in China, United States and India. Chong‐Rui Xu's co-authors include Yi‐Long Wu, Qing Zhou, Shun Lü, Wen‐Zhao Zhong, Chengping Hu, Mei Hou, Jifeng Feng, Jian Hua Shi, Yunchao Huang and Sarayut Lucien Geater and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.

In The Last Decade

Chong‐Rui Xu

112 papers receiving 4.3k citations

Hit Papers

Afatinib versus cisplatin plus gemcitabine for first-line... 2014 2026 2018 2022 2014 2017 2023 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    2014 1.6k citations Yi‐Long Wu, Chong‐Rui Xu et al. profile →
  2. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
    2017 333 citations Jian Su, Zhi Xie et al. OncoImmunology profile →
  3. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
    2023 110 citations Qing Zhou, Chong‐Rui Xu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chong‐Rui Xu China 27 3.5k 3.1k 1.0k 931 299 122 4.4k
Willemijn S.M.E. Theelen Netherlands 16 3.3k 0.9× 3.0k 1.0× 998 1.0× 873 0.9× 235 0.8× 33 4.4k
Hong‐Hong Yan China 31 2.8k 0.8× 2.5k 0.8× 870 0.9× 866 0.9× 194 0.6× 133 3.7k
Radj Gervais France 24 4.0k 1.1× 3.7k 1.2× 1.1k 1.0× 617 0.7× 275 0.9× 83 5.2k
Jin‐Ji Yang China 36 3.9k 1.1× 3.5k 1.1× 1.2k 1.2× 1.1k 1.1× 166 0.6× 146 4.9k
Hiroaki Akamatsu Japan 28 3.8k 1.1× 3.5k 1.1× 1.2k 1.2× 1.1k 1.2× 195 0.7× 144 5.1k
Venice Archer United Kingdom 9 3.6k 1.0× 3.6k 1.2× 919 0.9× 663 0.7× 181 0.6× 16 4.6k
Maximiliano Van Kooten Argentina 9 3.7k 1.1× 3.3k 1.1× 1.1k 1.1× 623 0.7× 213 0.7× 14 4.5k
Mark S. Huberman United States 30 3.3k 0.9× 3.0k 1.0× 1.2k 1.2× 778 0.8× 215 0.7× 80 4.5k
Riyaz Shah United Kingdom 19 3.3k 0.9× 2.8k 0.9× 1.1k 1.1× 708 0.8× 146 0.5× 48 3.9k
Andrew Weickhardt Australia 23 2.3k 0.7× 2.3k 0.7× 967 0.9× 527 0.6× 265 0.9× 111 3.4k

Countries citing papers authored by Chong‐Rui Xu

Since Specialization
Citations

This map shows the geographic impact of Chong‐Rui Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chong‐Rui Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chong‐Rui Xu more than expected).

Fields of papers citing papers by Chong‐Rui Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chong‐Rui Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chong‐Rui Xu. The network helps show where Chong‐Rui Xu may publish in the future.

Co-authorship network of co-authors of Chong‐Rui Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Chong‐Rui Xu. A scholar is included among the top collaborators of Chong‐Rui Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chong‐Rui Xu. Chong‐Rui Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Huajun, Hai‐Yan Tu, Yanping Hu, et al.. (2025). A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). Journal of Hematology & Oncology. 18(1). 3–3. 3 indexed citations
3.
Chen, Ji, Mei-Mei Zheng, Wu Lv, et al.. (2025). Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer. Nature Reviews Clinical Oncology. 22(8). 546–565. 3 indexed citations
4.
Zhao, Chunyan, et al.. (2025). Multimodal radiomics integrating deep learning and clinical features for diagnosing multidrug-resistant tuberculosis in HIV/AIDS patients. Journal of Global Antimicrobial Resistance. 43. 134–142.
5.
Lin, Ying, Chong‐Rui Xu, Dongyang Jiang, et al.. (2024). Protocol for tyramide signal amplification immunohistochemical detection of Notch1 signaling in the vascular system. STAR Protocols. 5(4). 103519–103519. 1 indexed citations
6.
7.
8.
Wang, Ziyan, Zhi Guo, Wu Lv, et al.. (2024). Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions. Cancers. 16(2). 304–304.
9.
Feng, William W., Janice J.N. Li, Hong‐Hong Yan, et al.. (2024). PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial. Journal of Thoracic Oncology. 19(10). S6–S6. 2 indexed citations
10.
Yang, Haotian, Jiawen Wu, Song Zhao, et al.. (2024). Prognosis of Early-Stage HFpEF in the Community-Dwelling Elderly: The Northern Shanghai Study. ESC Heart Failure. 12(1). 229–238.
11.
12.
Deng, Jie, Hong‐Hong Yan, Ming‐Yu Yang, et al.. (2023). WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901). Journal of Thoracic Oncology. 18(11). S38–S39. 1 indexed citations
13.
Deng, Jia‐Yi, Lingling Yang, Zhihong Chen, et al.. (2023). Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(7). e007218–e007218. 23 indexed citations
14.
Zheng, Mei-Mei, Hai‐Yan Tu, Jin‐Ji Yang, et al.. (2021). Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. European Journal of Cancer. 150. 23–30. 19 indexed citations
15.
Hm, Wang, Zhang Cy, Hsin‐Jen Chen, et al.. (2021). 1741P Malignant effusion-derived non-small cell lung cancer organoid might be a feasible in vitro model for therapeutic screening. Annals of Oncology. 32. S1202–S1203. 1 indexed citations
16.
Xu, Chong‐Rui, Mingfeng Zhang, Xiaoxiao Peng, et al.. (2018). EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China. Thoracic Cancer. 9(7). 814–819. 42 indexed citations
17.
Wu, Yi‐Long, Qi Zhou, Hsi‐Feng Tu, et al.. (2018). P1.01-97 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC. Journal of Thoracic Oncology. 13(10). S500–S501. 1 indexed citations
18.
19.
Yang, Jin-Ji, Xu‐Chao Zhang, Jian Su, et al.. (2014). Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation. Clinical Cancer Research. 20(5). 1383–1392. 135 indexed citations
20.
Su, Li, et al.. (2011). Putative Rabbit Conjunctival Epithelial Stem/Progenitor Cells Preferentially Reside in Palpebral Conjunctiva. Current Eye Research. 36(9). 797–803. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Hong‐Hong Yan Breakdown of academic impact, for papers by Radj Gervais Breakdown of academic impact, for papers by Jin‐Ji Yang Breakdown of academic impact, for papers by Hiroaki Akamatsu Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Maximiliano Van Kooten Breakdown of academic impact, for papers by Mark S. Huberman Breakdown of academic impact, for papers by Riyaz Shah Breakdown of academic impact, for papers by Andrew Weickhardt
Rankless by CCL
2026